We are at the forefront
of a revolution in drug discovery targeting protein misfolding diseases 

Natural forces chiseled every fold and fault over thousands of years, forming the landscape at Torrey Pines Beach. Similarly, protein folding and misfolding are strongly influenced by physical and cellular forces.

TARGET SELECTION

High-Confidence Targets, Data Driven Analysis

We use monogenic or pathway genetic evidence, bioinformatics, deep biology, and clinical path analysis to target unmet medical needs

DRUG DISCOVERY

Disease Modifying Focus, Innovative Discovery Platform

We are developing a pharmacological chaperone screening platform tailored for each specific disease target, anchoring on protein stability, coupled with phenotypic and functionality readouts that directly address disease defects

TRANSLATIONAL RESEARCH

Specific and sensitive biomarkers will enable early patient idenfication, clinical stage readouts in target engagement and therapeutic efficacy

Biomarker Discovery, Precision Medicine

Protego Biopharma focuses on the discovery and development of first- or best-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis. We also target other monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperones approach previously exemplified by tafamidis, which was discovered and developed by our cofounders Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis. 

We have assembled a proven team and joined forces with world-class investors and collaborators who embrace our mission.
 
protein 1.png
IMG_4825_DxO.jpg

Our Team

INVESTORS
MPM_logo_4.10.14._LargerWeb-02.png
MPM_logo_4.10.14._LargerWeb-01.png
Lightspeed-2.png
one_big_gradient-01.png
image 6.png

Proteins are the workhorses of human biology. Integrity of protein structures is essential to protein’s physiobiological functions. Protein misfolding is increasingly recognized as an underlying cause of many chronic degenerative diseases, and may have two major consequences: 1) loss of biological function; 2) gain of toxicity or toxic function.

 

Protein homeostasis (proteostasis) is influenced by the energetics of protein folding, misfolding, and aggregation. Proteostasis is also affected by numerous regulated networks of interacting and competing biological pathways that control the biogenesis, folding, trafficking, and degradation of proteins present within and outside of the cells.

 

Protego’s technology tackles the protein misfolding problem through modulation of the energetics of protein or protein complexes by binding to small molecules such as pharmacological chaperones and/or by modulation of the cellular folding, secretory, and stress pathways. Protego’s approach builds on the proven pharmacological chaperones approach previously exemplified by tafamidis, discovered and developed by our cofounders Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis. The company also builds on the concept of correcting pathologic imbalances in protein homeostasis by specifically activating the unfolded protein response (UPR) with small molecules, to increase cellular folding capacity.

image 4 (1).png

Our Science

 
 
 

Contact Us

Protego Biopharma

3210 Merryfield Row,

San Diego, CA 92121

United States

Tel: (858) 242-1518

Email: info@protegobiopharma.com

We're located in JLabs in sunny
San Diego
We're located in JLabs in sunny San Diego